Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-pertussis-inactivated poliomyelitis vaccine
- Development stage
- Phase 1
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria-tetanus-pertussis-inactivated poliomyelitis vaccine (DTaP-IPV) developed by **Beijing Minhai Biotechnology** is an adsorbed acellular combination vaccine designed to protect against four major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. The vaccine is composed of diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus serotypes 1, 2, and 3. These components are adsorbed onto an aluminum-based adjuvant, such as aluminum hydroxide or aluminum phosphate, to enhance the immune response. By combining these antigens into a single injection, the vaccine aims to reduce the number of required shots for infants and children, thereby improving compliance with immunization schedules. It is currently undergoing Phase I clinical evaluation in China to assess its safety and immunogenicity in healthy infants and children aged 3 months to 6 years.
- Other names
- DTaP-IPV vaccineadsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis combination vaccineDTaP-IPV
02
Targets
FHA (Filamentous hemagglutinin)Bordetella pertussisDiphtheria toxinPoliovirus type 1 capsid D-antigenPoliovirus type 2 capsid proteinPoliovirus type 3 capsid D-antigen
Beyond the preview
Go deeper on diphtheria-tetanus-pertussis-inactivated poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-pertussis-inactivated poliomyelitis vaccine.